Sam­sung Bioepis launch­es a Rem­i­cade knock­off at a 35% dis­count; FDA OK’s a self-ad­min­is­tered ver­sion of Benlysta

→ The South Ko­re­an biosim­i­lar play­er Sam­sung Bioepis has launched a copy­cat of Rem­i­cade on the US mar­ket at a 35% dis­count to J&J’s list price for that ther­a­py. Rem­i­cade is J&J’s top earn­er, and the phar­ma gi­ant has filed suit to try and stop Sam­sung’s ri­val for be­ing in­tro­duced. There’s been con­sid­er­able spec­u­la­tion on how gener­ic ver­sions of bi­o­log­ics could im­pact pric­ing.

→ The FDA ap­proved a sub­cu­ta­neous for­mu­la­tion of Benlysta for lu­pus, mak­ing it pos­si­ble for pa­tients to switch from an IV ver­sion of the GSK drug to a self-ad­min­is­tered shot.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.